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Retinoic acid (RA) triggers antiproliferative effects
in tumor cells, and therefore RA and its synthetic
analogs have great potential as anticarcinogenic
agents. Retinoic acid receptors (RARs) mediate RA
effects by directly regulating gene expression. To
define the genetic network regulated by RARs in
breast cancer, we identified RAR genomic targets
usingchromatin immunoprecipitationandexpression
analysis. We found that RAR binding throughout the
genome is highly coincident with estrogen receptor
a (ERa) binding, resulting in a widespread crosstalk
of RA and estrogen signaling to antagonistically regu-
late breast cancer-associated genes. ERa- and RAR-
binding sites appear to be coevolved on a large scale
throughout the human genome, often resulting in
competitive binding activity at nearby or overlapping
cis-regulatory elements. Thehighly coordinated inter-
section between these two critical nuclear hormone
receptor signaling pathways provides a global mech-
anism for balancing gene expression output via local
regulatory interactions dispersed throughout the
genome.
INTRODUCTION
Retinoic acid (RA) plays a major role in physiological processes
ranging from embryonic development to homeostasis of adult
tissues and organs (Niederreither and Dolle, 2008). Importantly,
RA inhibits the growth and survival of cancer cells at pharma-
cological doses. The potent anticarcinogenic activity of RA is
generally thought to result from direct and indirect effects on
gene expression. Therefore a comprehensive analysis of the
genomic targets of RA action should provide a better under-
standing of the mechanism of RA action in the prevention and
treatment of cancer, as well as providing a framework that can
be extended to other RA functions in organ development and
homeostasis.
Previous work has identified two subfamilies of nuclear
receptors as major mediators of RA signaling, the retinoic acidreceptors (RARs) and the retinoid X receptors (RXRs) (Evans,
1988; Giguere et al., 1987; Mangelsdorf and Evans, 1995; Petko-
vich et al., 1987). RARs dimerize with RXRs; the resulting heter-
odimers function as transcription factors, thereby eliciting the
transcriptional effects of RA signaling. However, little is known
about the genomic targets and effects of the different isoforms
of the RARs. There is similarly scant information about themech-
anism or extent of crosstalk between RA signaling and other
nuclear hormone signaling pathways in a cellular context.
In breast cancer cells, RA and retinoids have been previously
shown to be associated with downregulation of several genes
essential for proliferation and survival (Liu et al., 1998; Zhou
et al., 1997). However, it has been unclear if such genes are
directly or indirectly regulated by RARs since liganded RAR-
RXR heterodimers are thought to function primarily as transcrip-
tional activators while repression is thought to be primarily
mediated by unliganded heterodimers interfering with basal
transcription (Chambon, 1996; Glass and Rosenfeld, 2000; Hu
and Lazar, 2000; Niederreither andDolle, 2008). Also, RA-induced
apoptosis in breast cancer cells has been shown to be associated
with upregulated expression of a handful of proapoptotic genes
(Donato and Noy, 2005; Donato et al., 2007). However, although
several genes implicated in the negative regulation of breast
cancer cell proliferation and survival have been identified as
RA responsive, theknowledgeof themechanismof transcriptional
regulation byRARs is fragmentary.Whether and howRAsignaling
intersects with estrogen signaling, which promotes proliferation,
has not been investigated on a genomic scale.
We therefore analyzed the genomic actions of RA through
RARa and RARg, which exert antiproliferative and apoptotic
effects of RA in the breast cancer cell line MCF-7. MCF-7 is
the most commonly used experimental system for the study of
estrogen receptor a (ERa)-positive breast tumors, affording us
the opportunity to compare the genomic effects of RA and
estrogen signaling (Levenson and Jordan, 1997). Estrogen
signaling, in contrast to RA signaling, drives proliferation and
promotes survival and has been extensively studied in this cell
line. To uncover the transcriptional networks of RARa and RARg,
we have integrated genome-wide binding site mapping with
gene expression profiling. We found that RA signaling regulates
the expression of many genes that have been implicated in
breast carcinogenesis and/or whose expression is indicative
for the clinical outcome of breast cancer. Interestingly, we foundCell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc. 1259
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Figure 1. Genome-wide Identification of RARg- and RARa-Binding Sites in MCF-7 Cells
(A) Distribution of RARg- RARa-, and ERa-binding sites residing within 10 kb upstream or downstream to annotated transcription start sites (TSSs).
(B) Cumulative frequency of RARg- and RARa-binding sites for each 1 kb interval within 10 kb upstream or downstream to known TSSs.
(C–G) KnownRAR-binding sites identified by ChIP-chip analyses. Black bars depict binding regions for RARg and RARa. Known promoter-proximal RAR-binding
sites forHOXA1,HOXA4,HOXB1,CYP26A1, and FOXA1were identified by genome-widemapping inMCF-7. In addition, novel RAR-binding sites 30 to FOXA1 (F)
and CYP26A1 (G) (denoted by red rectangles) were identified.
(H and I) Novel binding regions for CYP26A1 (H) and FOXA1 (I) enhance expression of reporter constructs upon RA treatment. Upon RA agonist treatment these
constructs markedly enhanced firefly luciferase expression compared to the original pGL4.23 construct. Error bars represent standard deviation (SD).that RARa/RARg exhibit extensive colocalization of their
genomic binding regions with ERa in the vicinity of genes that
are antagonistically regulated by estrogen and RA.
RESULTS
Identification of Genomic RAR Target Sites
To define the RAR transcriptional network, we first mapped
the genomic binding sites of RARa and RARg. Because none of
the commercially available isoform-specific antibodies were
adequate to render high-quality chromatin immunoprecipitation
(ChIP) (data not shown), we used bacterial artificial chromosome
(BAC) transgenesis (Poser et al., 2008) togenerate two transgenic
MCF-7 lines, which stably express RARa and RARg tagged with
eGFP at their C termini at physiological levels (Figures S1A–S1E
available online). A total of 7346 high-confidence RARa-binding
sites and 3916 RARg sites were identified by ChIP-chip analysis
in the transgenic cells treated with synthetic receptor-selective
agonists for 1 hr using a p value cut-off of 1e-4 (Table S1 and
Figures S2A and S2B). Alternatively, we applied a p value cut-off
of 1e-3 to identify lower-confidence binding regions (Table S2).
We validated 40 randomly selected binding regions by ChIP-1260 Cell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc.qPCR (quantitative PCR) and found all of the tested regions
significantly enriched compared to genomic input DNA (Figures
S3A–S3C) indicating a very low number of false positives in the
ChIP-chip experiments. The binding sites of the two isoforms
showed a marked overlap as 3238 (82.7%) of the RARg sites
were found to be within 1 kilobase (kb) to RARa sites. Since
RARa is expressed at a higher level thanRARg, the larger number
of sites for RARa might reflect an increased binding probability
due to the higher abundance of this transcription factor. Overall,
the large proportion of RARa/RARg common target sites indi-
cates a high degree of functional redundancy as suggested by
mouse knockout studies (Lohnes et al., 1994).
Identification of RAR-binding sites has previously focused on
promoter andpromoter-proximal regions of RA-regulated genes,
andso far only a small numberof direct targets are known (Balmer
andBlomhoff, 2002; Niederreither andDolle, 2008). However, we
found only a small portion of RAR-binding sites mapped to
promoter-proximal regions (Figures 1A and 1B). Hence, most
RAR-binding sites were found in intronic or promoter-distal inter-
genic regions previously undefined as RAR-binding sites. Within
the list of RAR-binding sites in promoter or in promoter-proximal
regions, we confirmed a number of previously characterized
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Figure 2. Colocalization of RARa-, RARg-,
and ERa-Binding Regions and Antagonistic
Effects on Gene Expression between RA
and Estrogen Signaling
(A) Transcriptional response of RAs in MCF-7 cells
is mediated by RARs. x axis denotes Log2 trans-
formed fold changes in gene expression after RA
agonist treatment (100 nM AM580/CD437) relative
to vehicle control (DMSO) treatment in mock RNAi
experiments. Only genes with significant expres-
sion changes (1.5-fold change) are shown. y axis
shows Log2 transformed fold changes in gene
expression after RA treatment relative to vehicle
control treatment in RARg and RARa knockdown
cells (siRARs, blue spots) and in RNAi control cells
(siNT1, red spots).
(B) Venn diagram displaying shared regions bound
by RARg, RARa, and ERa. ERa-binding sites are
based on the union of two recent genomic studies
(Carroll et al., 2006; Hua et al., 2008).
(C) Venn diagram displaying shared putative target
genes of RARg, RARa, and ERa, as defined by
the presence of at least one binding region within
50 kb to the TSSs.
(D) Comparison of time course gene expression
profiles induced by estrogen and different RA
agonist treatment for 1413 RA-regulated genes.
Genes containing binding sites within 50 kb to
the TSSs are denoted by blue (RARg, RARa, or
ERa) and red bars (RARs and ERa).
(E and F) Comparison of gene expression changes
in response to estrogen and RA agonists. x axis
shows Log2 transformed fold changes in gene
expressionafter estrogen (10nME2) treatment rela-
tive to control (EtOH) treatment for 24 hr. y axis
shows Log2 transformed fold changes in gene
expression after RA agonist treatment (100 nM
AM580 and 100 nM CD437) relative to vehicle
control (DMSO) treatment for 72 hr in control-
treated (siNT1) MCF-7 cells (E) and ERa-depleted
(siER) MCF-7 cells (F). Genes with fold changes
greater than 1.5 or less than 1.5 for both x and
y axes are highlighted in red or blue, respectively.functional RAR sites for known RA-inducible genes, including
several HOX family genes (Figures 1C–1E),CYP26A1 (Figure 1F),
and FOXA1 (Figure 1G) (Balmer and Blomhoff, 2002). Interest-
ingly, we found additional novel RAR-binding sites nearby
some of these genes, such as 30 binding sites for FOXA1 and
CYP26A1 (Figures 1F and 1G). We tested whether these sites
could act as regulatory elements using a luciferase reporter
assay, and both were able to drive the reporter gene expression
in an RA agonist-dependent manner (Figures 1H and 1I).
RAR-Dependent Regulation of Gene Expression
To correlate the binding site data with the transcriptional effects
of the RARs, we performed gene expression profiling after ligand
treatment. Because the physiological ligand all-trans retinoic
acid (ATRA) can elicit transcriptional effects independent from
binding to RARs, e.g., through PPARd (Schug et al., 2007), we
generated expression profiles for ATRA and RAR-selective
agonists AM580 (RARa-specific) and CD437 (RARg-specific).
Comparisons between these expression profiles showed a highdegree of correlation (Figure S4). CD437 and AM580 elicited
similar transcriptional effects, consistent with the large overlap
observed for the binding sites of RARa and RARg.
To test whether the transcriptional response of the two selec-
tive agonists is mediated by RARs, we used RNAi to analyze
gene expression changes upon RAR depletion in the presence
and absence of the agonists. Knockdown of RARa and RARg
decreased or reverted most transcriptional changes caused by
AM580 and CD437 (Figure 2A). This result demonstrates that
both activation and repression of most genes in MCF-7 cells
by RA agonists require RARs.
We analyzed expression changes after treatment with all
individual ligands and the combination of AM580 and CD437 in
triplicates over a time course (0, 24, 48, 72 hr).We also compared
the gene expression profiles upon ligand treatment in a gene
expression time course aimed at identifying early-response
direct targets (0, 4, 12, 24 hr). We observed a relatively small
number of significant transcript changes in the 0–24 hr time
course compared to the 0–72 hr time course. Overall, weCell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc. 1261
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Figure 3. Antagonistic Actions of RARs and ERa Bound to Shared Regulatory Elements
(A and B) Distance between binding region centers of ERa and RARa (A) or RARg (B).1262 Cell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc.
identified a total of 1413 genes (Benjamini-Hochberg adjusted
p % 0.0005) (Table S3), which were significantly regulated by
RA and RA agonists. Three hundred and six showed differential
expression within the first 24 hr of ligand treatment. For a large
proportion of transcripts differentially expressed in the 0–72 hr
time course (46.5%) (hypergeometric test, p = 2.30e-140), we
observed RAR-binding sites within 50 kb to the transcription
start site (TSS) of the regulated gene, indicating that about
half of the RA-regulated genes represent direct effects of
liganded RAR rather than secondary effects. Previous work
investigating the role of liganded RARs in the regulation of
transcription has mainly focused on activation of expression,
while the repressive function has been thought to be mediated
mainly by unliganded RARs. However, downregulated tran-
scripts constitute a large fraction (52.8%) of RA-dependent
expression changes inMCF-7 cells, andwe observed nomarked
bias of RAR binding toward ligand-activated or -repressed
genes (52.5% and 41.2%, respectively). RAR regions are highly
significantly enriched in both up- and downregulated genes
(p = 4.03e-92 and p = 2.20e-50, respectively). Further, we
demonstrate for six putative RAR direct target genes, which
were significantly downregulated or upregulated by RA agonists,
that neither RA-mediated repression nor RA-mediated activation
require de novo protein synthesis (Figures S5A–S5F). Collec-
tively, these findings support the hypothesis that both activation
and repression involve binding of liganded RARs at target genes.
ERa- and RAR-Binding Regions Colocalize and Mediate
Antagonistic Actions on Gene Expression
We and others have mapped ERa binding genome wide in
MCF-7 cells (Carroll et al., 2006; Hua et al., 2008; Lin et al., 2007).
When we compared RAR-binding regions with ERa regions, we
found a marked colocalization. 39.3% of ERa regions were
observed within 1 kb of RAR-binding regions (Figure 2B). At the
gene level therewas an even larger overlap; ERa andRARs share
59.8% of their putative target genes as defined by the presence
of at least one binding region within 50 kb to the TSS (Figure 2C).
The extensive colocalization of RAR and ERa genomic binding
sites suggested potential crosstalk of RA and estrogen signaling
in the regulation of gene expression. To systematically identify
transcripts that are differentially regulated by RA agonists and
estrogen, we analyzed changes in gene expression after treat-
ment with estrogen and compared these results with our RAagonist data (Figures 2D and 2E). We found 139 genes downre-
gulated by RA agonists to be upregulated by estrogen, while 185
estrogen-repressed genes were upregulated by RA agonists.
A considerably smaller number of genes were upregulated (37)
or downregulated (103) by both estrogen and RA agonists.
Thus, the RA and estrogen signaling pathways appear to mainly
antagonize each other. We further validated this result by testing
the effects of RA agonists before and after the RNAi depletion of
ERa. Knockdown of ERa increased the number of both upre-
gulated and downregulated transcripts upon RA treatment
(Figure 2F). We also analyzed the effects of single treatment
with RA agonists and E2 or simultaneous cotreatment on the
expression of nine individual target genes that were associated
with unique RAR or ERa regions or ERa/RAR-binding regions
(Figures S6A–S6C). RA agonists and E2 had an antagonistic
effect on the expression levels of common target genes but
not on unique targets of RARs or ERa, whose expression levels
were affected by RA agonists or E2, respectively. Collectively,
these findings indicate an extensive crosstalk of ERa and
RARs to regulate gene expression. However, despite their
opposing effects on the majority of target genes, ERa and
RARa appear to activate each other. We observed ERa binding
in the proximity of the RARA TSS (Figure S7A) and upregulated
expression of RARA upon estrogen treatment. Likewise RARa
bound near the TSS of ESR1 (Figure S7B) and RA agonist treat-
ment led to upregulated expression of ESR1. This crossregula-
tion between the two antagonizing transcription factors presents
an additional level of control for achieving a balanced regulation
of gene expression by the two signaling pathways.
Antagonistic Actions of RARs and ERa Bound to Shared
Regulatory Elements
In order to determine the major mechanism of the global ERa/
RAR antagonism we performed a series of additional computa-
tional analyses and experiments. First, we analyzed the distance
between the putative binding sites of ERa and RARs in overlap-
ping binding regions. Using the center of a binding region as the
putative binding site, we found that most ERa- and RAR-binding
sites occur within 100 nt (Figures 3A and 3B). Considering the
resolution limit of ChIP-chip, this finding indicates that most
binding sites of ERa and RARs occur very close to each other,
overlap, or are identical. This finding suggests competitive
binding for the same genomic binding sites or steric hindrance(C and D) Ratios of normalized ChIP versus input signal intensities for the putative FOXA1 and FOS regulatory regions. Ratios were calculated from three repli-
cates. Coordinates refer to UCSC hg16.
(E and F) Histone 3 (H3) acetylation is antagonistically regulated by E2 and RA agonists at FOXA1 and FOS regulatory regions. RARg-LAP MCF-7 cells grown in
medium with charcoal-stripped FBS were either treated with vehicle or E2 (10 nM) for 45 min. The medium of E2-treated cells was then changed with medium
containing vehicle (a), or CD437 (100 nM) (b), or a mixture of E2 (10 nM) and CD437 (100 nM). RA denotes CD437. Relative fold enrichment was determined by
ChIP-qPCR using a pan-specific antibody against Acetyl-H3.
(G–J) ERa and RARg-LAP recruitment is antagonistically regulated by E2 and RA agonists at FOXA1 and FOS regulatory regions. Relative fold enrichment was
determined by ChIP-qPCR using an antibody against ERa or eGFP using the chromatin obtained from the experiment described above (E and F).
(K and L) FOXA1 and FOS regulatory regions do not cobind ERa and RARg-LAP. RARg-LAP MCF-7 cells grown in medium with charcoal-stripped FBS were
treated with E2 (10 nM) and CD437 (100 nM) for 2 hr. The first ChIP was performed with an antibody against ERa. Immunoprecipitated chromatin was eluted
and a second ChIP was performedwith IgG (negative control) or antibody against eGFP (targeting RARg-LAP) or Acetyl-H3 (positive control). Relative enrichment
was determined for the re-ChIPed chromatin by qPCR.
(M and N) ERa/RAR-binding region for FOS exhibits a differential response to estrogen and RA agonists. FOS and FOXA1 regulatory regions (FOS_2, FOXA1_1,
Table S9) cloned into Firefly luciferase vector pGL4.23 were cotransfected into MCF-7 cells with the Renilla luciferase vector pGL4.73 used to correct for trans-
fection efficiency. All error bars represent SD.
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between close sites. By manual inspection of ERa- and RAR-
binding events using normalized ChIP-chip intensities, we found
that many overlapping regions have nearly identical peaks
(Figures S8A–S8R). RARa as well as RARa-RXR dimers bind
in vitro to synthetic and natural estrogen response elements
(EREs) (IR3) by gel-shift assays (Klinge et al., 1997; Naar et al.,
1991) and can compete with ERa for binding to EREs (Joyeux
et al., 1996) (R.K., S.H., and K.P.W., data not shown). To test
the model of competitive binding in vivo we chose two example
elements where RARs and ERa overlap. The first was a putative
regulatory element of FOXA1, whose gene expression is upregu-
lated by RA agonists and downregulated by E2 (Figure 3C). The
second was a putative regulatory element of FOS, whose gene
expression is upregulated by E2 and downregulated by RA
agonists (Figure 3D). We tested the effects of RA agonists and
E2 treatment on H3 acetylation and ERa and RARg recruitment
at these two ERa/RAR-binding regions. E2 decreases and RA
agonists increase H3 acetylation for the FOXA1 element
(Figure 3E), while opposite effects were observed for the FOS
regulatory element (Figure 3F), indicating that the antagonistic
effects of RA and E2 on gene expression are mediated through
opposite effects on cofactor recruitment to common ERa/RAR
sites. These opposite effects on H3 acetylation were also corre-
lated with changes in ERa and RARg recruitment. Upon initial E2
treatment, ERa recruitment was found to be increased for both
regions, but subsequent treatment with RA agonists in absence
of E2 led to a decrease in ERa binding and an increase in RARg
binding, which could be reverted by simultaneous cotreatment
with E2 and RA agonists (Figures 3G–3J). This finding supports
A B
C D
Figure 4. Enriched Hormone Response
Elements and Evolutionary Conservation of
RAR- and ERa-Binding Regions
(A) Canonical HREs are composed of two half-
sites (PuGGTCA) separated by a variable-length
spacer. Hormone response elements (HREs) can
be configured as direct repeats (IR), everted
repeats (ER), or inverted repeats (IR).
(B) Motif enrichment analysis for all HREs with
spacer lengths from 0 to 10 in RARa- or RARg-
binding regions, RAR and ERa common regions
(ERa/RAR), and RAR unique regions (RAR only).
(C) Conservation profiles of RAR and ERa common
sites (depicted in red), RAR unique sites (depicted
in green), and ERa unique sites (depicted in blue).
The conservation profile of local genomic back-
ground is depicted in black.
(D) Conservation profiles of IR3 and DR5 motifs
and 30 bp flanking regions in RAR and ERa
common sites (depicted in red), RAR unique sites
(depicted in green), and ERa unique sites (de-
picted in blue). The conservation profile of all pre-
dicted IR3 or DR5 motifs and 30 bp flanking
regions in the human genome is depicted in black.
a model of competitive binding of ERa
and RARg. To further corroborate this
hypothesis, we tested whether ERa and
RAR were cobound to the FOXA1 and
FOS elements by Re-ChIP and qPCR.
Consistent with a competitive binding mechanism, no simulta-
neous cobinding of RAR and ERa at these regulatory elements
was observed in vivo (Figures 3K and 3L).
Taking these results together, we propose that competition for
the same binding element, overlapping elements, or very close
elements presents one mechanism for the antagonistic regula-
tion of genes with common ERa/RAR-binding regions. Such
closely overlapping binding sites are found within the majority
of ERa and RAR target genes (71%). In addition, it is notable
that 557 out of the 1913 (29.1%) ERa and RAR common putative
target genes do not contain colocalized ERa- and RAR-binding
sites. Thus, while convergent regulation of common target genes
by RA and estrogen signaling may occur predominantly through
binding shared regulatory regions, it may in a substantial minority
of cases also occur through independent regulatory regions via
longer-range effects.
To determine whether genomic regions with shared ERa and
RAR binding have regulatory potential when removed from their
genomic context we used a simple luciferase reporter assay. We
tested the responsiveness to RA agonists and E2 for seven ERa/
RAR-binding regions aswell as two unique RAR-binding regions.
RAR-only regions were responsive to RA agonists but not to E2
(Figures S9A and S9B). Two of the ERa/RAR-binding regions (a
GREB1 element and the FOS element shown in Figures S9C
and 3D, 3F, 3H, 3J, 3L, and 3N) mediated an antagonistic
response to E2 and RA agonists, while the other elements
were responsive to either E2 or RA agonists (including the
FOXA1 element shown in Figures 3C, 3E, 3G, 3I, 3K, and 3M
and a BTG2 element shown in Figure S9D) or did not show any
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response (data not shown). These results indicate that colocal-
ized binding elements for ERa andRARs can sometimes be suffi-
cient to cause the antagonizing effect of estrogen and RA on
gene expression. However, there might be alternative mecha-
nisms that require the integrated action of multiple cis-regulatory
elements to differentially regulate expression by estrogen and
RA. In this context, we note that a considerable proportion of
putative direct ERa or RAR target genes (25.5% and 35.6% for
ERa and RARs, respectively) contain more than one binding
site within 50 kb to the TSSs. Also, RAR and/or ERa actions at
common regions may require a specific chromatin status that
cannot be recapitulated with reporter plasmids.
Enriched HREs and Evolutionary Conservation
of RAR-Binding Sites
We searched all RAR-binding sites for the presence of putative
retinoic acid response elements (RAREs). To perform an unbi-
ased analysis, we calculated the enrichment for all canonical
hormone response elements (HREs), i.e., two direct (DR), in-
verted (IR), and everted (ER) hexameric PuGGTCA repeats with
half-site spacer lengths from 0 to 10 (Figure 4A). This analysis
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Figure 5. FoxA1 and GATA3 Binding Coin-
cides with ERa and RAR Binding
(A andB) Venn diagramof FoxA1-, ERa-, andRAR-
binding sites (A) or GATA3, ERa, and RAR sites (B).
(C and D) Percentages of ERa unique sites, RAR
unique sites, and ERa and RAR common sites
colocalized with FoxA1 (C) or GATA3 (D) binding
sites.
(E) Effect of FoxA1 knockdown on RAR recruit-
ment. Recruitment of RARg (defined as fold
enrichment relative to input DNA) was quantified
by qPCR after ChIP using an eGFP antibody
comparing depleted (siFoxA1) and control cells
(siNT1). Reduced RARg recruitment was only
observed for seven RARg sites colocalizing with
FoxA1 sites but not for two unique RARg sites or
a negative control site. Error bars represent SD;
***p < 0.001.
identified DR5, which is frequently
present in known RAR-binding sites, as
the most significantly enriched HRE in
our in vivo RAR-binding regions
(Figure 4B). We also noticed a significant
enrichment for several other types of
HREs. For some of them, e.g., DR0,
DR1, DR10, IR0, and ER8, there is exper-
imental evidence supporting their role as
RAREs (Mangelsdorf et al., 1994).
However, we also found HREs signifi-
cantly enriched that have not been impli-
cated as RAREs before, e.g., ER2.
Regions with colocalization of ERa and
RAR binding showed a significant enrich-
ment for the canonical estrogen response
element (ERE) IR3 and several known
RAREs such as DR5, indicating that ERa
and RARs may bind to canonical response elements in shared
binding regions. However, when we compared the enrichment
of IR3 and DR5 between unique and colocalizing ERa- and
RAR-binding regions, respectively, we observed a reduced
enrichment in the colocalizing regions (Figures S10A and
S10B). This latter result indicates that an indirect binding mech-
anism may play an important role for the recruitment of both
RARs and ERa to these elements.
We examined the evolutionary conservation of regions bound
by ERa and RAR among vertebrates. Both ERa- and RAR-
binding regions showed relatively high sequence conservation
as compared to genomic background (Figure 4C). Likewise,
IR3 and DR5 elements were found to be conserved in these
regions (Figure 4D), supporting their putative roles as functional
cis-regulatory elements. Interestingly, colocalizing binding
regions for ERa and RARs showed a slight but significantly
higher conservation than ERa or RAR unique sites (p = 1.21e-10
and p = 2.29e-5, respectively), which may indicate a higher func-
tional constraint for the shared cis-regulatory regions. We
observed for these regions a markedly higher conservation for
IR3 elements than for unique ERa- or RAR-binding regions,
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whichmay indicate a prevalent role of IR3 for the function of ERa/
RAR-binding regions.
Transcription Factor Motifs in RAR-Binding Sites
To identify putative transcription factors that specifically facilitate
the binding of RARs and/or coregulate transcriptional effects of
RARs, we searched all RAR-binding regions for enrichment of
known transcription factor motifs. This analysis identified a
number of putative binding motifs from several transcription
factor families (Figure S10C and Table S4). Significantly enriched
motifs were found for AP-1, Forkhead, and GATA transcription
factors, which all have been previously reported to be highly
enriched in ERa-binding sites (Carroll et al., 2006; Hua et al.,
2008). While motifs for these factors were significantly enriched
when we considered all RAR sites, the most significant enrich-
ment of Forkhead and GATA motifs was found in ERa/RAR
common binding regions. For the AP-1 (Fos) motif, we observed
a markedly higher enrichment in both unique RAR-binding
regions and ERa/RAR common binding regions compared to
unique ERa-binding regions (Figure S10C).
FoxA1 and GATA3 Binding Coincides
with RAR and ERa Binding
FoxA1 and GATA3 are likely candidates for Forkhead and
GATA family members that are binding to the motifs enriched
in regions with RAR genomic binding. Transcription factors
such as FoxA1 have been proposed to act as pioneering tran-
scription factors that facilitate the binding of ERa to enhancer
elements (Carroll et al., 2005; Laganiere et al., 2005; Lupien
et al., 2008). GATA transcription factors have been shown to
mediate long-range chromatin interactions (Ansel et al., 2006).
In particular, GATA3 is an essential regulator of mammary
luminal cell fate, is coexpressed with ERa in breast carcinomas,
and is a strong predictor of breast cancer differentiation (Kouros-
Mehr et al., 2008; Lacroix and Leclercq, 2004). To validate
specific FoxA1 and GATA3 associations with the enriched Fork-
head and GATA motifs in RAR-binding sites, we performed
ChIP-chip analysis using a FoxA1-specific antibody or a GFP
antibody with BAC-transgenic GATA3-eGFP cell line, respec-
tively. We identified 8061 high-confidence FoxA1- and 972
GATA3-binding regions, which we typically found distal to TSSs
(Figures S2C and S2D) as observed for ERa- and RAR-binding
regions. These regions significantly colocalized with ERa- and
RAR-binding regions (Figures 5A and 5B). Also, FoxA1- and
GATA3-binding regions exhibited a marked colocalization
(Figures S11A–S11D). As predicted by the motif enrichment
analysis, FoxA1- and GATA3-binding sites showed the highestoverlap with shared ERa/RAR elements (Figures 5C and 5D).
Unique RAR-binding regions exhibited a lower frequency of
FoxA1 and GATA3 binding, which further decreased for unique
ERa-binding regions. These findings indicate that both FoxA1
and GATA3 may be bona fide coregulators for RARs and ERa
and play in particular an important role for the function of shared
ERa/RAR-binding elements.
FoxA1 Is Required for RAR Recruitment
FoxA1 was recently shown to facilitate ERa recruitment by
inducing chromatin opening at ERa enhancers (Carroll et al.,
2005; Lupien et al., 2008). To determine whether there is a similar
role of FoxA1 for RAR recruitment, we quantified RARg binding
upon FoxA1 knockdown by quantitative PCR. For this analysis
we selected from our ChIP-chip data seven sites that were found
to bind both RARg and FoxA1, two sites that bound RARg
but not FoxA1, and a negative control site that bound neither
RARg nor FoxA1. We found that FoxA1 depletion significantly
decreased RARg binding for all seven RARg/FoxA1-binding
sites tested, but not for the RARg sites without FoxA1 binding
(Figure 5E). Thus, FoxA1 is required for RAR recruitment to
specific target sites. We also tested whether GATA3 is required
for RAR binding and found that GATA3 depletion had no effect
on RAR recruitment (data not shown), suggesting that GATA3
functionmay be compensated for by FoxA1 or other GATA family
factors. To further investigate the role of FoxA1 and GATA3
in RA signaling, we profiled the effects of FoxA1 and GATA3
depletion on RA-regulated gene expression. Knockdown of
FoxA1 had a significant effect (Figure S12A), while GATA3 deple-
tion had only a minor effect on many RA-regulated transcripts
(Figure S12B). Importantly, FoxA1 depletion affected the expres-
sion of genes with adjacent FoxA1/RAR regions but had typically
no effect on RA-regulated genes adjacent to unique binding RAR
regions.
Together, these findings indicate that the primary interaction
of RARs with chromatin might utilize similar mechanisms as
have been proposed for ERa. Importantly, the motif enrichment
analysis predicts that HRE-independent recruitment requiring
FoxA1, GATA3, and AP-1 may play a key role for the binding
of ERa and RARs to shared binding elements. In this context it
is worthy to note that FOXA1,GATA3, and FOS are also putative
direct targets of ERa and RARs with overlapping binding regions
(Figures S7C–S7E) that are antagonistically regulated by
estrogen and RA. Whereas the expression of FOS and GATA3
(Eeckhoute et al., 2007) is activated by estrogen and according
to our data repressed by RA, we found the expression of FOXA1
to be upregulated by RA and downregulated by estrogen. TheseFigure 6. RAR Targets as Breast Cancer-Relevant Genes
(A) Network view of functional modules enriched in RA-regulated genes. Each node represents a functional module or set of biologically relevant genes (see also
Table S7). The node size is proportional to the minus logarithm of the adjusted p value for testing the module enrichment of RA-regulated genes. Edge width
correlates with the minus logarithm of the adjusted p value for testing the enrichment between functional modules.
(B) Hierarchical clustering of 146-breast tumor set using the UNC Intrinsic gene set (Hu et al., 2006). The density profiles for RARg, RARa, and ERa putative
targets, as well as RAR and ERa common targets, were plotted. The density was calculated as the proportion of transcription factor putative targets in 50 neigh-
bors for each gene in the cluster.
(C and D) RAR targets as prognostic indicators. Kaplan-Meier curves of overall survival (C) and relapse-free survival (D) among the 295 patients (van de Vijver
et al., 2002) classified by RA signature values. The patient samples are grouped in three categories based on RA signature scores: P (positive RA score)
(n = 73), N (negative RA score) (n = 74), and U (uncorrelated) (n = 148). p values were obtained from log-rank tests.
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crossregulatory loops for putative common cofactors may be
a key part of the transcriptional ERa/RAR circuitry mediating
the antagonizing effects of estrogen and RA signaling in breast
cancer cells.
ERa- and RAR-Dependent Gene Regulation in Breast
Cancer
RAR-binding site mapping and expression profiling in MCF-7
cells revealed a marked antagonistic crosstalk between RA and
estrogen signaling in this breast cancermodel. Becauseestrogen
signaling is a key pathway in breast carcinogenesis, we surmised
that genes regulated by RAmight also play a major role and thus
have an important diagnostic and therapeutic value. Indeed,
many putative RAR direct targets that are frequently also ERa
direct targets have an established role in breast cancer or impor-
tant cellular pathways (see Table S5 and Figures S7A–S7S and
S13A–S13F).
To systematically validate the role of RAR-mediated transcrip-
tional regulation in breast cancer, we analyzed the enrichment of
RA-regulated genes inMCF-7 cells in functionalmodules (Subra-
manian et al., 2005) or gene signatures that have been previously
associated with breast cancer. RA-regulated genes in MCF-7
cells are highly enriched in a number of breast cancer-relevant
signatures (Figure 6A). Notably, the signatureBC1000 comprised
of 1347manually curated genes implicated in breast cancer (Witt
et al., 2006) is among the most enriched modules for RA-regu-
lated genes. Two hundred and twenty-nine out of these 1347
(17.0%, multiple testing adjusted p = 3.03e-19) putative breast
cancer genes are significantly regulated by RA in MCF-7 cells,
and 108 out of those 229 RA targets have RAR-binding elements
within 50 kb of the TSS (Figure 6A and Table S6). We also
observed a very significant enrichment (multiple testing adjusted
p = 5.32e-22) of the signature composed of genes regulated by
GATA3 (Oh et al., 2006). RA-regulated genes in MCF-7 cells
were found to be enriched in sets of genes that are both positively
and negatively correlated with ER status in breast tumors
(Table S7) (p = 1.24e-14 and p = 1.72e-10, respectively). Finally,
we observed that RA-regulated genes are enriched in several
cancer modules or functionally related genes that are condition-
ally activated or repressed in a variety of cancer types (Table S7)
(Segal et al., 2004), indicating that RARmight act as a direct tran-
scriptional regulator for a subset of genes within these cancer
modules.
The meta-analysis described above suggests that many genes
regulated by RA in MCF-7 cells are breast cancer relevant. We
next analyzed the expression of putative direct RAR targets that
were derived from our cell line experiments in breast tumor cells
frompatient samples. For this purpose,weanalyzedgeneexpres-
sionprofilesof 146breast cancerpatient samples (Huet al., 2006).
These expression profiles were previously used to classify breast
tumors into distinct intrinsic subtypes (e.g., Luminal, Basal-like,
HER2+/ER) that differ in their clinical outcomes (Hu et al.,
2006). When we analyzed RAR and ERa binding in the genes
comprising these expression profiles, we observed that a gene
cluster with high expression in Luminal type but low expression
inmoreaggressive subtypes (Basal-likeandHER2+/ER) contains
ahighproportionofRAR targets aswell asERa targets (Figure6B).
This groupof genes is characterized byhighexpressionof ERa, its1268 Cell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc.putative coregulators (e.g., FOXA1, GATA3), and known direct
targets (e.g.,TFF1,KRT18). Interestingly,wealso foundgeneclus-
ters with high expression in Basal-like and HER2/ER subtypes
but low expression in Luminal and Normal-like types to contain
a large fraction of genes that are putative direct targets of RARa
and RARg but not of ERa (Figure 6B).
Our observations that many RAR targets are breast cancer-
relevant genes and are specifically expressed in different breast
cancer subtypes suggested that these genes might possess a
significant prognostic value. We therefore analyzed the clinical
outcome for each tumor sample dependent on the expression
of putative direct targets of RARs. For this analysis, we defined
for each tumor sample an RA signature score, which measures
the correlation between RA-dependent gene expression profiles
in MCF-7 cells and the gene expression profile in a given tumor
sample for putative RAR direct targets (See Experimental Proce-
dures). We first examined the correlation between RA signature
scores and clinical outcomes for a cohort of expression profiles
from 295 breast tumor patients (van de Vijver et al., 2002). A total
of 354 putative RAR direct targets were identified in this dataset.
Kaplan-Meier survival analysis demonstrated a highly significant
correlationbetweenRAsignatures and thepatient overall survival
(Log-rank test, p = 6.53e-6) and a significant correlation for
relapse-free survival (Log-rank test, p = 5.48e-3) (Figures 6C
and 6D). Positive RA signature scores indicated good prognosis
while negative scores strongly indicated poor clinical outcomes.
We also observed significant correlation between RA signature
and standard clinical-pathologic indexes, such as tumor grade,
tumor size, and ERa status (Table S8). These results were
confirmed for two independent breast tumor cohorts (Figures
S14A and S14B).
DISCUSSION
Comparing the overlap of different transcription factors can be a
powerful means of inferring functional relationships, particularly
when combined with expression data. Our results indicate that
RARa- and RARg-binding sites frequently overlap in the human
genome, andcomparisons of geneexpression in response to iso-
form-specific agonists indicate considerable redundant function.
Previousmodels of gene regulation by these crucial physiological
and developmental regulators have been restricted by the focus
on binding to promoters or promoter-proximal gene regions
(Balmer and Blomhoff, 2002; Niederreither and Dolle, 2008).
However, we found that the majority of RAR-binding sites occur
distal to TSSs. These results are reminiscent of recent studies
that have revealed a similar tendency for ERa to bind to distal
elements (Carroll et al., 2006; Hua et al., 2008; Lin et al., 2007).
The cofactor FoxA1 has been implicated in this recruitment of
ERa to distal sites (Carroll et al., 2005; Lupien et al., 2008), and
our results indicate that FoxA1 is similarly required for RAR
recruitment to genomic binding sites. Likewise, GATA3 binding
frequently coincides with ERa and RAR binding, although it is
not strictly required for RAR recruitment. Strikingly, many of the
genomic regions bound by RARs overlapped with those previ-
ously identified to bind ERa. Subsequent transcriptional analysis
demonstrated that RARs and ERa tend to exhibit antagonistic
effects on the transcription of target genes.
This can occur either through independent cis-regulatory
elements or, more frequently, via shared binding regions of
ERa and RARs (Figure 7A). In the specific instances we tested,
ERa and RAR binding were mutually exclusive, indicating
competitive binding of the two nuclear receptors to the same
element or nearby cis-regulatory elements. Based on the known
functions of their target genes in breast cancer, ERa and RARs
appear to be ‘‘Yin and Yang’’ for the genetic regulation of prolif-
eration and survival that are promoted by ERa and inhibited
B
A
Figure 7. A Model for the Antagonistic Regulation of Target Genes
by RAR and ERa
(A) The antagonistic regulation of target genes by RAR and ERa can occur
either through independent cis-regulatory elements or, as wasmost frequently
found, through shared binding regions of ERa and RARs. FoxA1 and GATA3
may be essential for RAR- and/or ERa-mediated gene regulation. FoxA1
may act as an initial chromatin binding factor and facilitate further recruitment
of the RAR/RXR heterodimer, ERa homodimer, and/or other cofactors. The
line and arrow width indicates the frequency that FoxA1 or GATA3 participates
in different types of RAR or ER regulatory regions. Motif enrichment analysis
predicts a potential role for AP-1 in ERa and RAR recruitment to these sites.
(B) Transcriptional regulatory circuits composed of RAR, ERa, and their puta-
tive cofactors. The expression of FOXA1, GATA3, and FOS in MCF-7 cells is
oppositely regulated by RAR and ERa upon RA or estrogen treatment. A nega-
tive feedback is achieved by positive crossregulation between the two antag-
onizing transcription factors RAR and ERa.by RARs. The finding that binding sites of RARs and ERa are
coincident within the same enhancers or located in different
enhancers for the same target genes, along with the finding
that these two nuclear receptor signaling systems antagonisti-
cally regulate their target genes, indicates that these regulatory
elements are coevolving to balance target gene expression.
Interestingly, the ERa/RAR antagonism appears to regulate itself
through crossregulatory loops between ERa, RARs, and their
cofactors (Figure 7B). This balanced control of gene expression
regulates fundamental cellular processes that when dysregu-
lated can lead to cancer.
The identification of the genes regulated by RARs in breast
cancer cells, and in particular the discovery of their extensive
crosstalk with estrogen signaling, may benefit breast cancer
diagnostics and therapeutic intervention. Specifically, RAR-
and ERa-binding data can diagnostically differentiate tumor
subtypes and patient outcome. Putative direct targets of ERa
and RARs in MCF-7 cells are highly expressed in Luminal type
breast tumors, indicating that their antagonistic effects may be
relevant for primary ER-positive tumors. However, RARs appear
to be important regulators of cancer-relevant genes that are not
regulated by estrogen. We found such RAR targets to be ex-
pressed at high levels in Basal-like and HER2/ER tumors that
are typically highly aggressive and associated with poor prog-
nosis. Importantly, we demonstrated that in breast tumor
samples, the expression of RAR targets identified in MCF-7 cells
predicts apositive clinical outcome. Someof these genesmaybe
targets for diagnosis and/or therapeutic intervention. Based on
these findings, there is a strong rationale for the use of RA
agonists in breast cancer treatment. However, success of RA-
based therapies has been limited to treatment of acute promye-
locytic leukemia (Altucci et al., 2007; Soprano et al., 2004), while
clinical applications of RA in breast and other solid tumors have
shown limited effects due to RA resistance (Freemantle et al.,
2003; Schug et al., 2007). To harness the RA-mediated anticarci-
nogenic effects of RARs in breast cancer, this resistancemust be
overcome, perhaps via inhibition of FABP5 to block metabolism
of RA into PPARd agonists (Schug et al., 2008). Another potential
approach would be the use of selective agonists or combination
therapy with anti-estrogens in ER+/RAR+ patients. Alternatively,
RA resistance could be bypassed by targeting RA-regulated
genes and pathways that mediate the antineoplastic effects of
RA in breast cancer; in this study, we have uncovered the frame-
work of these effects.
EXPERIMENTAL PROCEDURES
Generation of BAC Transgenic MCF-7 Cell Lines
The BACs CTD-2343G9 (RARA), CTD-2644H7 (RARG), and RP11-1103A14
(GATA3) were obtained from Invitrogen. A LAP cassette was inserted as a
C-terminal fusion using ET cloning; BAC DNA was extracted and transfected
into MCF-7 breast cancer cells (ATCC HTB-22) for the generation of stable
BAC transgenic cell lines as previously described (Poser et al., 2008).
Luciferase Reporter Assays
RAR- and ERa/RAR-binding regions were cloned into pGL4.23 (Promega).
MCF-7 cells were transfected with pGL4.23 (containing the binding regions
or the empty vector) and pGL4.73 using Lipofectamine LTX (Invitrogen),
treated with agonists or vehicle, and assayed using the Dual-Glo Luciferase
assay (Promega).Cell 137, 1259–1271, June 26, 2009 ª2009 Elsevier Inc. 1269
Reverse Transfection with siRNAs
Reverse transfection was carried out at a concentration of 50 nM of control
siRNA or four siRNAs (ON-TARGETplus SMARTpool, Dharmacon) directed
against the same target gene using Dharmafect 1 transfection reagent (Dhar-
macon).
Chromatin Immunoprecipitation Experiments
Cells at 80% confluency (5 3 106 cells per ChIP) were subjected to ChIP as
previously described, with the following antibodies: goat anti-GFP (raised
against His-tagged full-length eGFP and affinity-purified with GST-tagged
full-length eGFP), goat anti-FoxA1 (ab5089) from Abcam, anti-panH3ac
(06-599) from Millipore, and anti-ERa (MC-20, sc-542x) and normal goat IgG
(sc-2028) from Santa Cruz Biotechnologies.
For ChIP-qPCR assays, the fold enrichment of ChIPed DNA relative to input
DNA at a given genomic site was determined by comparative CT (DD CT)
method using StepOnePlus Real-Time PCR System and Power SYBR Green
PCR Master Mix (Applied Biosystems) according to the manufacturer’s
protocol. An ACTB exonic region or 18S rRNA genomic region was used for
normalization. All primer sequences used for qPCR are described in Table S9.
For ChIP-chip, both ChIPed DNA and input DNA were subjected to linker-
mediatedPCRamplificationand fragmentationandend-labeledwithbiotinusing
the GeneChip WT Double-Stranded DNA Terminal Labeling Kit (Affymetrix) as
previously described. The resulting labeled samples were hybridized to Affyme-
trix GeneChip Human Tiling 2.0R Array Set following the Affymetrix Chromatin
Immunoprecipitation Assay Protocol. Independent biological triplicates were
performed for each transcription factor, as well as the control (input DNA).
qRT-PCR and Microarray Gene Expression Profiling Experiments
qRT-PCR was performed with cDNA generated from total RNA from MCF-7
cells treated with different agonists and/or transfected with siRNAs. Relative
expression levels for specific genes were determined using StepOnePlus
Real-Time PCRSystem andPower SYBRGreen PCRMasterMix (Applied Bio-
systems). All primer sequences used for qRT-PCR are described in Table S9.
For expression profiling, total RNA samples were labeled by direct incorpora-
tion of cyanine 3-labeled CTP using the Agilent Low RNA Input Linear Amplifi-
cation Kit PLUS (One-Color) (Agilent Technologies) and hybridized to Agilent
Human Genome Oligo Microarrays (4 3 44K) (Agilent Technologies). Hybrid-
ized microarrays were scanned using a GenePix 4000B scanner (Molecular
Devices) at 5 mm resolution. All experiments were performed in triplicate.
Data Analysis
ChIP-chip tiling array data were normalized and analyzed with Affymetrix Tiling
Analysis Software (TAS) as previously described (Bernstein et al., 2005) using p
value cut-offs of 1e-4 (for detecting high-confidence binding regions) or 1e-3
(for detecting lower-confidence binding regions, Figures S15A–S15C). For
the analysis of gene expression data the software package LIMMA (Smyth,
2004) was applied to detect significantly differentially expressed probes. The
enrichment of known or predicted transcription factor binding motifs in
ChIP-identified RAR- or FoxA1-binding regions was estimated by comparing
the number of motifs in binding regions with the number of motifs in randomly
selected genomic regions. Associations between RA-responsive genes and
clinical and pathologic variables were examined using a Chi-Square contin-
gency test with the JMP7 software package (SAS Institute Inc.). Patient sample
data grouped into three RA signature categories were used to plot Kaplan-
Meier survival curves for patient overall survival or relapse-free survival.
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